• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing CareDx (CDNA) Valuation After ImmuneScape Multiomics Collaboration With 10x Genomics

    Simply Wall St·01/07/2026 14:36:32
    語音播報

    CareDx (CDNA) has drawn fresh attention after announcing ImmuneScape, a multiomics research initiative with 10x Genomics that uses single cell and spatial platforms to study transplant rejection biology and treatment response.

    See our latest analysis for CareDx.

    The ImmuneScape announcement comes after a period of mixed trading, with a recent 1-day share price decline of 5.05% to US$18.81 but a 90-day share price return of 27.70%. The 1-year total shareholder return decline of 21.62% contrasts with a 3-year total shareholder return of 37.50% and a 5-year total shareholder return decline of 77.69%. This suggests near-term momentum has picked up even as longer-term holders have seen a wide range of outcomes.

    If you are watching how transplant focused diagnostics stories evolve, it could also be worth scanning other healthcare stocks that are reshaping care in different corners of the sector.

    With ImmuneScape shining a spotlight on CareDx’s transplant toolkit and the share price rebounding over the past 90 days, the central question is whether the current valuation still leaves room for upside or if markets are already pricing in future growth.

    Most Popular Narrative Narrative: 18.2% Undervalued

    With the most followed narrative putting fair value at US$23.00 against a last close of US$18.81, the gap between price and expectations is clear and raises questions about what is built into the assumptions.

    The analysts have a consensus price target of $21.833 for CareDx based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $28.0, and the most bearish reporting a price target of just $14.0.

    Read the complete narrative.

    Curious what justifies that higher fair value? Revenue growth forecasts, shifting margin expectations, and a richer future earnings multiple sit at the center of this narrative.

    Result: Fair Value of $23 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this hinges on reimbursement and regulatory outcomes, as tighter LCD policies or Medicare coverage shifts on key tests could quickly challenge those higher fair value assumptions.

    Find out about the key risks to this CareDx narrative.

    Build Your Own CareDx Narrative

    If you would rather test the numbers yourself and stress test these assumptions directly, you can build your own CareDx view in just a few minutes, starting with Do it your way.

    A great starting point for your CareDx research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

    Looking for more investment ideas?

    If you are serious about broadening your opportunity set, do not stop at one company. Use the Simply Wall St Screener to quickly surface focused ideas across different themes.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.